Another bispecific CD19/CD22 CAR that uses a tandem approach showed good efficacy in 6 patients with r/r B-ALL and observed one relapse of blast cells with loss of CD19 antigen and diminished CD22 expression 5 months after treatment (NCT03185494 (137)). Here, CD22 is linked to acute lymphoblastic leukemia.